Treatment of hepatitis B: The next five years

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 7, Issue 5, 2007, Pages 472-477

  Heathcote, E Jenny ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antiviral therapy; Chronic hepatitis B; Drug resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; HEPATITIS B VACCINE; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE;

COMBINATION CHEMOTHERAPY; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MONOTHERAPY; NEPHROTOXICITY; PATIENT EDUCATION; POLYMERASE CHAIN REACTION; REVIEW; RNA INTERFERENCE; VIRUS LOAD; VIRUS REPLICATION;

EID: 35748986141     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.7-5-472     Document Type: Review

References (31)

1. Liaw YF, Sung JJ, Chow WC et al; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for Patients with chronic hepatitis B and advanced liver disease. N Eng J Med 2004;351:1521-31.
2. Perrillo RP, Gish RG, Peters M et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006;4:233-48.
3. D'Antiga L, Aw M, Atkins M et al. Combined lamivudine/interferon- alpha treatment in 'immunotolerant' children perinatally infected with hepatitis B: a pilot study. J Peditrics 2006;148:228-33.
4. Yang HI, Lu SN, Liaw YF et al; Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Eng J Med 2002;347:168-74.
5. Chen CJ, Yang HI, Su J et al; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
6. Evans AA, O'Connell AP, Pugh JC et al. Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 1998;7:559-65.
7. Yang LM, Xu KC, Zhai YL et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Die Dis 2002;3:150-3.
8. Kim HC, Nam CM, Jee SH et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004;328:983.
9. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
10. Locarnini S, Hatzakis A, Heathcote J et al. Management of antiviral resistance in patients with chronic hepatitis B. Antiviral Therapy 2004;9:679-93.
11. Lok AS, Yim HJ, Hussain M et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12.
12. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36:687-96.
13. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002;16:131-3.
14. Lau GK, Piratvisuth T, Luo KX et al; Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Eng J Med 2005;352:2682-95.
15. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
16. Lai CL, Leung N, Teo EK et al; Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:52-836.
17. Lampertico P, Vigano M, Manenti E et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005;42:1414-9.
18. Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005;54:1610-4.
19. Iloeje HU, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130: 678-86.
20. Flink HJ, van Zonneveld M, Hansen BE et al; HBV 99-01 Study Group. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006;101:297-303.
21. Ito K, Tanaka Y, Orito E et al. T1653 mutation in the box alpha increases the risk of hepatocellular carcinoma in patients with chronic hepatitis B virus genotype C infection. Clin Infect Dis 2006;42:1-7.
22. Liu CJ, Chen BF, Chen PJ et al. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J Infect Dis. 2006;193:1258-65.
23. Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005;128:1890-7.
24. Feld J, Lee JY, Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003;38:545-53.
25. Wu HL, Huang LR, Huang CC et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant. Gastroenterology 2005;128:708-16.
26. Uprichard SL, Boyd B, Althage A, Chisari FV. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA 2005;102:773-8.
27. Heathcote J, McHutchinson J, Lee S et al. A pilot study of CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 1999;30:531-6
28. Sherman A, Tsang T, Wang CB et al. Mass screenings in New York City reveal high prevalence of Hepatitis B in an urban Asian population. Hepatology 2005;42. Abstract.
29. Tawk HM, Vickery K, Bisset L et al; Infection in Endoscopy Study Group. The current pattern of hepatitis B virus infection in Australia. J Viral Hep 2006;13:206-15.
30. Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Eng J Med 1997;336:1855-9.
31. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ 2006;332:328-36.